Press release
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
Fetal Focus achieved 96% sensitivity and 98% specificity in validation from the prospective blinded EXPAND clinical trial AUSTIN, Texas--(BUSINESS WIRE)--
About this update from Natera, Inc.
[{"type":"text","content":"\nFetal Focus achieved 96% sensitivity and 98% specificity in validation from the prospective blinded EXPAND clinical trial\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s expanded 21-gene Fetal Focus single gene non-invasive prenatal test (sgNIPT), supported by new findings from the blinded prospective EXPAND clinical trial. Results from this analysis demonstrate the test’s ability to detect a broader set of clinically relevant inherited conditions with high accuracy.\n\n\nThe latest readout from EXPAND included 193 prospectively-collected clinical samples associated with the 16 new genes in the panel. In this new cohort, Fetal Focus achieved 100% sensitivity (14/14) for identifying affected pregnancies and 94.2% observed specificity. Combined with data reported previously from the EXPAND trial, Fetal Focus has now demonstrated overall 96% sensitivity (24/25 affected pregnancies) and 98% population-weighted specificity in 294 total samples across the full 21 genes. These results represent the first prospective, blinded validation for an expanded set of conditions, with confirmatory diagnostic testing for all positive and negative cases.\n\n\nFetal Focus analyzes cell-free DNA circulating in maternal blood to assess whether a fetus has inherited disease-causing variants from one or both parents. The test is an option for pregnant patients who test positive with Natera’s Horizon™ carrier screen when the father is unavailable for guideline-recommended carrier testing1. In addition to the initial five genes, the updated test incorporates 16 additional genes associated with severe or early-onset disease, including Tay-Sachs disease, Gaucher disease, and galactosemia.\n\n\nLaunched in 2023, the EXPAND trial has enrolled more than 1,800 participants from leading academic medical centers and maternal-fetal medicine practices, reflecting a diverse, multi-ethnic population. In the initial readout, Fetal Focus correctly identified all five cases affected by homozygous variants2,3, a category that is particularly challenging because the fetus inherits the same disease-causing variant from both parents. Fetal Focus uses Natera’s proprietary ultra-sensitive LinkedSNP™ technology to support detection of these cases across diver...